XPRIZE Healthspan — A 7-year, $101 Million Global Competition To Revolutionize The Way We Approach Human Aging — Dr. Jamie Justice, Ph.D., — Executive Vice President, Health, XPRIZE Foundation.

Venture Investing To Catalyze The Next Generation Of Founder-Led, Longevity Biotech Companies — Dr. Alex Colville, Ph.D., Co-Founder and General Partner — age1.

Dr. Alex Colville, Ph.D. is Co-Founder and General Partner of age1 (https://age1.com/), a venture capital firm focused on catalyzing the next generation of founder-led, longevity biotech companies, with a strategy of building a community of visionaries advancing new therapeutics, tools, and technologies targeting aging and age-related diseases.

With a recent initial closing of US$35 million, age1 will be focusing on founders and companies at the earliest stages of first-money in, pre-seed and seed funding, and is resourced to continue to support companies through later rounds.

Dr. Colville previously established the biotech arm of Starbloom Capital and served as founding Chief of Staff of Amaranth Foundation, where he led: the foundation’s support of skilled researchers and ambitious moonshot projects in the longevity field, and helped to advance their lobbying efforts; the TIME Initiative (a group with mission to activate undergraduate students’ interest in aging biology); the Marine Biology Laboratory Biology of Aging Summer Course, among other programs.

Dr. Colville completed his Ph.D. in Genetics at Stanford University studying the biology of aging in Dr. Thomas Rando’s lab while consulting for several family offices, the R&D team of Rubedo Life Sciences, and the business development team of Maze Therapeutics. Prior to his Ph.D., while at Northeastern University completing his Bachelor of Science (B.S.) in Chemical Engineering with a Minor in Biochemical Engineering, he advised pharma companies as a management consultant at Putnam Associates, a boutique life sciences consulting firm.

Leveraging Technology For Innovative, Patient-Centered Clinical Care — Dr. Peter Fleischut, MD — Group Senior Vice President And Chief Information & Transformation Officer, NewYork-Presbyterian Hospital

Dr. Peter M. Fleischut, M.D., is Group Senior Vice President and Chief Information and Transformation Officer at NewYork-Presbyterian (https://www.nyp.org/)where he oversees the strategic vision and management of enterprise information technology, lab operations, pharmacy operations, innovation, data and analytics, artificial intelligence, telemedicine, and cybersecurity.

Dr. Fleischut has led the development of the Hospital’s award-winning digital health services and the implementation of clinical operations at NewYork-Presbyterian David H. Koch Center, a world-class ambulatory care center. In his previous role as Senior Vice President and Chief Transformation Officer, he focused on creating a single electronic medical record across NewYork-Presbyterian and its affiliated medical schools, Weill Cornell Medicine and Columbia University Vagelos College of Physicians and Surgeons.

Dr. Fleischut also led efforts to standardize care across NYP’s ten hospitals and hundreds of clinics and doctor practices, and oversaw all aspects of Graduate Medical Education (GME) for programs across the NYP enterprise.

Joining NewYork-Presbyterian/Weill Cornell in 2006, Dr. Fleischut previously served as Medical Director of Operating Rooms, Deputy Quality Patient Safety Officer, founding Director of the Center for Perioperative Outcomes, Vice Chairman, Chief Medical Information Officer, Chief Innovation Officer and Chief Medical Operating Officer.

In 2016, Dr. Fleischut became Vice Chair of the Department of Anesthesiology at Weill Cornell Medical College, where he is an Assistant Professor of Anesthesiology. He is a graduate of Jefferson Medical College and the Wharton Program for Working Professionals at the University of Pennsylvania.

Dr. Fleischut has received numerous awards and honors, including NewYork-Presbyterian’s Physician of the Year, Modern Healthcare Up and Comers, Becker’s Hospital Review 40 under 40, and the American Telehealth Association President’s Award.

NewYork-Presbyterian is one of the nation’s most comprehensive, integrated academic health care delivery systems, dedicated to providing the highest quality, most compassionate care and service to patients in the New York metropolitan area, nationally, and throughout the globe. In collaboration with two renowned medical schools, Weill Cornell Medicine and Columbia University Vagelos College of Physicians and Surgeons, NewYork-Presbyterian is consistently recognized as a leader in medical education, groundbreaking research, and innovative, patient-centered clinical care.

Revolutionizing Musculoskeletal Health Through Microcapsule Drug Delivery — Dr. @George R. Dodge, Ph.D. — CEO & Co-Founder — Mechano-Therapeutics LLC

Dr. George R. Dodge, Ph.D. is CEO & Co-Founder of Mechano-Therapeutics LLC (https://mechano-therapeutics.com/), a biotechnology company spun out from his lab, and the labs of his partners Dr. Rob Mauck and Dr. Daeyeon Lee, at the University of Pennsylvania, specializing in microcapsule development using proprietary microfluidics for drug encapsulation, with a mission to revolutionize musculoskeletal health using an innovative platform technology to enhance delivery of therapeutics for improving patient outcomes.

Dr. Dodge recently served on the faculty of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania; as Director, Philadelphia VA Shared Instrument Core; and Director, Translational Musculoskeletal Research Center, Philadelphia Crescenz Veterans Administration Medical Center, Department of Veteran Affairs.

Dr. Dodge has a B.S. (Biology) from Asbury College, a B.S. (Biology and Health Science / Public Health) from State University of New York, a Ph.D. (Biochemistry and Immunology) from McGill University, and did Post-Graduate work in Molecular and Cell Biology, at Thomas Jefferson University Department of Pathology and Cell Biology.

Dr. Dodge is an established investigator with a career long commitment to translational musculoskeletal research and in particular research focused on cartilage and chondrocyte biology, extracellular matrix and research related to osteoarthritis.

Discovering And Developing Medicines To Keep You Biologically Young — Dr. Marco Quarta, Ph.D. — Co-Founder and CEO, Rubedo Life Sciences; CEO, Phaedon Institute.

Dr. Marco Quarta, Ph.D. is Co-Founder and CEO of Rubedo Life Sciences (https://www.rubedolife.com/), a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. The company’s proprietary ALEMBIC drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders.

Dr. Quarta received his doctorate degree in Biotechnology from the University of Bologna and a Ph.D. in Neuroscience from the University of Padua. He completed a post-doc in Aging and Stem cell Biology in the lab of Prof. Thomas Rando at Stanford University and continued his work at Stanford directing a research team at the Center for Tissue Regeneration, Repair, and Restoration at the VA Hospital in Palo Alto, CA. While there, he established a translational program in regenerative medicine. He has over 35 publications and patents in the field of aging, stem cells, regenerative medicine, and rejuvenation.

Dr. Quarta also co-founded Wetware Concepts, Young European Biotech Network (YEBN), and Turn Biotechnology, and served as an executive board member of the European Federation of Biotechnologies. He currently sits on the advisory board of the California Institute for Regenerative Medicine (CIRM) Calpoly Bridge program, and the advisory board at the Center for Healthcare Innovation. He is a member of the Paul F Glenn Center for the Biology of Aging Studies at Stanford University, one of the most prestigious institutions supporting the science of aging.

Dr. Quarta also serves as CEO and President for the Board of Directors of The Phaedon Institute (https://www.phaedon.institute/), a think-tank organization that operates with the mission of supporting and enabling effective and sustainable growth in the field of aging and longevity sciences.

Dr. Joni L. Rutter, Ph.D., (https://ncats.nih.gov/director/bio) is the Director of the National Center for Advancing Translational Sciences (NCATS — https://ncats.nih.gov/) at the U.S. National Institutes of Health (NIH) where she oversees the planning and execution of the Center’s complex, multifaceted programs that aim to overcome scientific and operational barriers impeding the development and delivery of new treatments and other health solutions. Under her direction, NCATS supports innovative tools and strategies to make each step in the translational process more effective and efficient, thus speeding research across a range of diseases, with a particular focus on rare diseases.

By advancing the science of translation, NCATS helps turn promising research discoveries into real-world applications that improve people’s health. The NCATS Strategic Plan can be found at — https://ncats.nih.gov/strategicplan.

In her previous role as the NCATS deputy director, Dr. Rutter collaborated with colleagues from government, academia, industry and nonprofit patient organizations to establish robust interactions with NCATS programs.

Prior to joining NCATS, Dr. Rutter served as the director of scientific programs within the All of Us Research Program, where she led the scientific programmatic development and implementation efforts to build a national research cohort of at least 1 million U.S. participants to advance precision medicine. During her time at NIH, she also has led the Division of Neuroscience and Behavior at the National Institute on Drug Abuse (NIDA). In this role, she developed and coordinated research on basic and clinical neuroscience, brain and behavioral development, genetics, epigenetics, computational neuroscience, bioinformatics, and drug discovery. Dr. Rutter also coordinated the NIDA Genetics Consortium and biospecimen repository.

Throughout her career, Dr. Rutter has earned an international reputation for her diverse and unique expertise via her journal publications and speaking engagements, and she has received several scientific achievement awards, including the 2022 Rare Disease Legislative Advocates–RareVoice Award for Federal Advocacy and the 2022 FedHealthIT–Women in Leadership Impact Award.

Dr. Rutter received her Ph.D. from the Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, New Hampshire, and completed a fellowship at NCI within the Division of Cancer Epidemiology and Genetics.

Dr. Scott O’Neill (PhD, FAA, FAAAS) is Founder of the World Mosquito Program (https://www.worldmosquitoprogram.org/en/work/about-us/team/scott-oneill) and Professor at Monash University (https://lens.monash.edu/@scott-oneill), where he leads a large international research collaboration (formerly known as Eliminate Dengue), which is focused on developing the Wolbachia bacteria as a novel method to block the transmission of dengue fever and other mosquito-transmitted viral diseases, such as Zika and chikungunya. This global, not-for-profit program is currently conducting field trials of the Wolbachia method in multiple countries, in areas where these diseases are endemic, working closely with communities, local health organizations and governments to implement its self-sustaining method through controlled releases.

Dr. O’Neill has spent his academic career at the University of Illinois, Yale University, the University of Queensland and Monash, where he was previously the dean of the Faculty of Science.

Dr. O’Neill is internationally recognized for his contributions to the field of insect symbiosis and the way the intimate bacterial associations of invertebrates are ubiquitous and can generate major effects on the reproductive physiology, developmental biology and ecology of the insects they infect. His work has made major contributions to understanding how insect symbionts exert their effects and the consequences for infected hosts.

Is the Ira Rubinoff Director of the Smithsonian Tropical Research Institute (STRI https://www.si.edu/about/bios/joshua-tewksbury), part of the Smithsonian Institution, the world’s largest museum, education, and research complex. He oversees more than 400 employees, with an annual budget of $35 million. Headquartered in Panama City, Panama, with field sites around the world, STRI furthers the understanding and public awareness of tropical biodiversity and its importance to human welfare. In addition to its resident scientists and support staff, STRI’s facilities are used annually by some 1,400 visiting scientists, pre-and postdoctoral fellows and interns from around the world.

Dr. Tewksbury is an ecologist with more than two decades of research in conservation and biodiversity, as well as nearly a decade of executive leadership experience at international research institutes.

Prior to his role at the STRI, Dr. Tewksbury was serving as Executive Director at Future Earth, a global research program dedicated to sustainability and global change, where he led a network of tens of thousands of scientists and managed a wide range of conservation research projects, staff, programs and partnerships.

In this role at Future Earth, Dr. Tewksbury oversaw dozens of interdisciplinary research projects, from assessing threats to biodiversity to understanding the relationship between human and environmental health. He has also founded initiatives like the Earth Leadership Program, which supported skills development for academic researchers working to address sustainability challenges. Previously, he was the founding director of the Luc Hoffman Institute, a global research center within World Wildlife Fund International focused on conservation science.

Dr. Tewksbury is also co-founder and executive editor of Anthropocene magazine, a publication that highlights sustainability solutions. He holds faculty positions at the University of Colorado at Boulder, Colorado State and George Mason University’s Department of Environmental Science and Policy. He also has an appointment as senior scholar with Colorado State University’s School of Global Environmental Sustainability and is a member of the National Academy of Sciences’ Board on Environmental Studies and Toxicology.

Over the course of his research career, Dr. Tewksbury has published more than 85 scientific papers on topics in conservation, climate change and natural history, including the relationships and diversity of tropical plants, animals and fungi. He holds a bachelor’s degree in field biology from Prescott College and a doctorate from the University of Montana in organismal biology and ecology.

Dr. Michael Roberts, Ph.D. is Chief Science Officer of the International Space Station National Laboratory (https://www.issnationallab.org/), and Vice President at the Center for the Advancement of Science in Space (CASIS — https://www.issnationallab.org/about/center-for-the-advancem…dership/), which as manager of the ISS National Laboratory in partnership with NASA, is responsible to the nation for enabling access to the International Space Station for research, technology development, STEM education, and commercial innovation in space as a public service to foster a scalable and sustainable low Earth orbit economy.

Before joining CASIS in 2013, Dr. Roberts worked as a microbial ecologist, principal investigator, and research group lead in the NASA Advanced Life Support program at the Kennedy Space Center.

Prior to arriving at NASA-KSC in 1999, Dr. Roberts completed an undergraduate degree in biology at Maryville College, a doctorate in microbiology at Wesleyan University and post-doctoral research at the Center for Microbial Ecology at Michigan State University and the RIKEN Institute in Wako-shi, Japan.

Is Program Manager, Advanced Research Projects Agency for Health (ARPA-H — https://arpa-h.gov/people/ross-uhrich/), which is focused on advancing high-potential, high-impact biomedical and health research that cannot be readily accomplished through traditional research or commercial activity, accelerating better health outcomes targeting society’s most challenging health problems.

Under the ARPA-H portfolio, Dr. Uhrich is responsible for the recently launched Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO — https://arpa-h.gov/engage/programs/nitro/) program which seeks to develop new ways of helping the human body repair its own joints, with the goal of revolutionizing treatment for osteoarthritis — a common and often very painful condition where bones and cartilage break down.

Dr. Uhrich joined ARPA-H in March 2023 from Walter Reed National Military Medical Center (WRNMMC) and the Uniformed Services University of the Health Sciences, where he worked as a board-certified oral and maxillofacial surgeon and assistant professor of surgery. In addition to these roles, he spent 12 years with the U.S. Navy, finishing his tenure as a Lieutenant Commander.

Throughout his career, Dr. Uhrich has cared for thousands of members of the U.S. Armed Forces at various healthcare facilities, including the USS Gerald R. Ford, Naval Health Clinic Quantico, and WRNMMC, and served as an oral and maxillofacial surgery consultant to Congress. He also treated patients at Charleston Area Medical Center, R Adams Cowley Shock Trauma Center, and Suburban Hospital.

Dr. Uhrich holds a doctorate in dental medicine from the University of Pennsylvania, an MBA from the University of Virginia, and completed his surgical residency at WRNMMC. He also has a Bachelor of Science in Biomedical Engineering from Yale University.